Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Type 2 Diabetes Mellitus: early-phase trial registry
15 of 131 indexed Type 2 Diabetes Mellitus trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #91 of 28,707 conditions by registered trial count.
131 US clinical trials · 15 currently recruiting · #91 of 28,707 conditions by registered trial count
Type 2 Diabetes Mellitus: 131 US clinical trials tracked, 15 recruiting.
Type 2 Diabetes Mellitus is the subject of 131 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 52 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 11 of these trials.
Enrollment posture brief
Registry condition type-2-diabetes-mellitus
OPEN 15 | RECR 11% | LATE 26 | EARLY 52 | RANK #91 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Actinic Keratosis (12% recruiting · 17 trials)
Type 2 Diabetes Mellitus lists 15 open slots (11% of 131 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Type 2 Diabetes Mellitus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Type 2 Diabetes Mellitus is recruiting below its size-band peers.
15 of 131 indexed trials (11.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Type 2 Diabetes Mellitus trials is spread across many organizations.
AstraZeneca accounts for 11 of 131 trials (8.4%). 82 distinct sponsors appear on at least one study for this condition label.
-
Typical Type 2 Diabetes Mellitus enrolment sits around 70 participants.
Median target enrolment is 70 among the 131 trials that report a genuine target (sentinel values excluded). 76 of those (58%) plan for fewer than 100 participants.
-
Type 2 Diabetes Mellitus research is mostly interventional.
116 interventional and 15 observational studies make up this index (88.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
131 total, page 3 of 3
Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?
Baylor College of Medicine
NCT01040819
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
Gilead Sciences
NCT01546558
Determinants of Diabetes Remission After Gastric Bypass Surgery
Blandine Laferrere
NCT02287285
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
Sanofi
NCT03376802
A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol
Sanofi
NCT02940379
Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine
Gilead Sciences
NCT01546597
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
University of Colorado, Denver
NCT03620773
Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes
Baylor College of Medicine
NCT01432405
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients
AstraZeneca
NCT01221545
Pilot Study of the Effects of Erythritol on Endothelial Function in Patients With Type 2 Diabetes Mellitus
Boston University
NCT01609088
A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes
Medidata Solutions
NCT02227303
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
University of California, San Francisco
NCT02846233
The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass
Adrian Vella
NCT01843881
Pilot Study Of The Effects Of Resveratrol On Endothelial Function In Subjects With Type 2 Diabetes Mellitus
Boston University
NCT01038089
Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection
Theracos
NCT03167411
Metabolic Effects of Pulse Consumption on Biomarkers in Adults With Type 2 Diabetes or Met Syn
Iowa State University
NCT05145998
Fiber Mix and Glycemic Response
Rutgers, The State University of New Jersey
NCT03334643
Vitamin D and Adipose Tissue Inflammation
Fred Hutchinson Cancer Center
NCT01477034
The Set-Point Study for Type 2 Diabetes: Evaluating the Use of an Insulin Only Bionic Pancreas System in Type 2 Diabetes
Massachusetts General Hospital
NCT03552523
Acute Metabolic Effects of LAF 237 in Type 2 Diabetics
The University of Texas Health Science Center at San Antonio
NCT00230464
Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus
Lexicon Pharmaceuticals
NCT01188863
ECC5004 RBA FE Study in Healthy Participants
Eccogene
NCT06268145
Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
Nick Giannoukakis, PhD
NCT02597101
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus
AstraZeneca
NCT00254254
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
Mayo Clinic
NCT02762708
A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers
GlaxoSmithKline
NCT00501930
Lipid, Glycemic, and Insulin Responses to Meals Rich in Different Fatty Acids
University of Texas Southwestern Medical Center
NCT00479791
Impact of Gastric Bypass Surgery on Risk of CVD in Type 2 Diabetes Mellitus
Vanderbilt University
NCT00444392
Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects
AstraZeneca
NCT00908271
Guide To Goals: A Novel Care Coordination Tool for Children With Type Two Diabetes (T2D)
Georgia Institute of Technology
NCT03926598
Medically Reproducing Bariatric Surgery
Moahad S Dar
NCT03225209
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 29 |
| Phase 2 | 23 |
| Phase 3 | 16 |
| Phase 4 | 10 |
Top Sponsors
Named interventions
Most-linked intervention names on Type 2 Diabetes Mellitus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Type 2 Diabetes Mellitus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Type 2 Diabetes Mellitus page
131 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Type 2 Diabetes Mellitus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Type 2 Diabetes Mellitus trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Type 2 Diabetes Mellitus condition card totals 131 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.